



November 18, 2025

Company name LinqMed Inc.
Representative Yukie Yoshii, President and CEO

LinqMed Announces Completion of the Chiba Factory

LinqMed Inc. (President and CEO: Yukie Yoshii; Headquarters: Chiba City, Chiba Prefecture; hereinafter, the “Company”), a company engaged in the development of radiopharmaceuticals with the aim of bringing its “innovative visible cancer therapy” to society as quickly as possible, hereby announces that it has constructed a new factory in Chiba City, Chiba Prefecture, capable of manufacturing the radioisotope ^{64}Cu (copper-64), which is used in “Visible” cancer radiotherapeutics, as well as radiopharmaceutical products, and that it has held a completion ceremony and factory tour.



Overview of the Chiba Factory

The Chiba Factory is equipped with a cyclotron and pharmaceutical manufacturing facilities required to establish a domestic mass-production system for radiopharmaceuticals using ^{64}Cu . The purpose of the facility is to establish a Japan-originated drug discovery support platform that can rapidly develop “visible” cancer therapeutics using ^{64}Cu as next-generation pharmaceuticals, and to create a new industrial foundation. The equipment centered on the cyclotron, which is necessary for research aimed at achieving this purpose, has received support from the New Energy and Industrial Technology Development Organization (NEDO). In addition, the facility has sufficient manufacturing capacity to deliver the Company’s first development product, ^{64}Cu -ATSM (LM001), to patients across Japan once it is launched. ^{64}Cu -ATSM is currently being evaluated in a Phase III investigator-initiated clinical trial in patients with recurrent or refractory malignant glioma, among the most difficult-to-treat malignant brain tumors (STEP-64 study, study number NCCH2301).



Overview of the Completion Ceremony


With the completion of the factory, which the Company has planned since its founding to enable the manufacture of the radioisotope ^{64}Cu and radiopharmaceutical products, we held a completion ceremony and factory tour on November 4, 2025. The ceremony was attended by many stakeholders, including Governor Kumagai of Chiba Prefecture and Deputy Mayor Hashimoto of Chiba City.



Yukie Yoshii, LinqMed Inc.

There were many challenges on the path to completion of the factory, but we were able to reach this point by overcoming them together as one team, working closely and sharing ideas with Daiken Sekkei, Inc., which was responsible for the design, and Shinnihon Corporation, which was responsible for the construction. We believe that being able to celebrate this day by joining forces with many stakeholders, including Chiba Prefecture, Chiba City, and NEDO, embodies our motto, "Link for Life," which means connecting advanced science with medicine and connecting people with one another. We would like to express our sincere gratitude to everyone who has provided support and cooperation.

From this factory, we will continue to place safety first and strive to deliver high-quality, cutting-edge medicines to patients as soon as possible.



Factory tour: From left, Mr. Toshihito Kumagai, Governor of Chiba Prefecture; Mr. Naoaki Hashimoto, Deputy Mayor of Chiba City; and Yukie Yoshii, President and CEO of LinqMed Inc.

End

About LinqMed

LinqMed Inc. is an R&D start-up company developing radiopharmaceuticals to provide innovative “visible” anti-cancer treatments to patients. Our mission is “Link for Life -Linking Innovative Science and Medicine for Your Health and Happiness”. LinqMed Inc. has been launched as a certified venture company of the National Institutes for Quantum Sciences and Technology (QST). We are developing radiopharmaceuticals using a copper radioisotope ^{64}Cu , which can be used for diagnosis and therapy, simultaneously.

URL : <https://linqmed.net/>

Inquiries:

LinqMed Inc.

Email: linqmed@linqmed.co.jp